Pharma giant Eli Lilly acquires Washington University-founded startup Disarm Therapeutics for $135M

The company, based on the research of two of the university's scientists, is developing treatments for neurologic diseases like ALS, Parkinson's and multiple sclerosis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.